BioCryst Pharmaceuticals, Inc. (BCRX)
| Market Cap | 2.22B |
| Revenue (ttm) | 874.84M |
| Net Income (ttm) | 263.86M |
| Shares Out | 250.80M |
| EPS (ttm) | 1.21 |
| PE Ratio | 7.32 |
| Forward PE | 38.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,555,103 |
| Open | 9.04 |
| Previous Close | 8.90 |
| Day's Range | 8.80 - 9.15 |
| 52-Week Range | 6.00 - 11.31 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 20.82 (+134.99%) |
| Earnings Date | May 6, 2026 |
About BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for BCRX stock is "Strong Buy." The 12-month stock price target is $20.82, which is an increase of 134.99% from the latest price.
News
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
BioCryst to Report First Quarter 2026 Financial Results on May 6
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on...
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted ...
BioCryst Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Revenue growth is driven by strong U.S. performance, expanding prescriber base, and high patient retention among super-responders. The pipeline is advancing with navenibart and a KLK5 inhibitor, while pediatric and community market penetration continues to rise.
BioCryst Pharmaceuticals Earnings Call Transcript: Q4 2025
Delivered record 2025 revenue and profitability, driven by ORLADEYO growth and strategic portfolio expansion. 2026 guidance projects continued double-digit revenue growth, with new pediatric and injectable HAE therapies advancing and strong U.S. market focus.
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on...
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46th Annual Health Car...
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedem...
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2025 financial results on ...
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initia...
BioCryst Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Record ORLADEYO growth, European divestiture, and the Astria acquisition marked a transformative year, with profitability achieved and a strong cash position. ORLADEYO is on track for $1B peak sales by 2029, while pipeline assets like navenibart and BCX17725 drive future growth.
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
–Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)–
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcar...
FDA expands approval of BioCryst's rare disease drug for use in young children
The U.S. Food and Drug Administration has expanded the use of BioCryst Pharmaceuticals' drug to include an oral pellet formulation for preventing hereditary angioedema attacks in children aged 2 to un...
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to
– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early and s...
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition
RESEARCH TRIANGLE PARK, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has received early termination of the waiting period under the Har...
BioCryst Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Management outlined strong ORLADEYO growth, with $1B peak sales targeted by 2029, and detailed the strategic rationale and expected synergies from the Astria acquisition. Nevenabart is positioned for a late-2028 launch, while pipeline updates and disciplined expense management support ongoing profitability.
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)
– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early and sustai...
BioCryst Pharmaceuticals Earnings Call Transcript: Q3 2025
Orladeyo delivered 37% year-over-year revenue growth and maintained high patient retention despite new competition. The company improved its financial position by selling its European business, repaying debt, and raising guidance, while advancing its pipeline and preparing for the Astria acquisition.
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update
—Q3 2025 ORLADEYO net revenue of $159.1 million (+37 percent y-o-y)— —Q3 2025 operating profit of $29.6 million (+285 percent y-o-y); non-GAAP operating profit of $51.7 million (+107 percent y-o-y); ...
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meet...
BioCryst to Report Third Quarter 2025 Financial Results on November 3
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on M...
Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.